DBV Technologies S.A. (NASDAQ:DBVT) Receives Consensus Rating of "Hold" from Brokerages

Key Points

• DBV Technologies S.A. has received a consensus rating of "Hold" from seven analysts, with one strong buy, three buys, one hold, and two sell ratings.
• The company's current average price target among analysts is $14.75, indicating potential for stock growth from its current trading price of $12.90.
• DBV Technologies recently reported an earnings loss of ($1.55) EPS, significantly missing analyst expectations of ($0.21) EPS, while generating revenues of $1.74 million for the quarter.

DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) has been assigned an average recommendation of "Hold" from the seven analysts that are currently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $14.75.

Several equities research analysts have recently commented on DBVT shares. Wall Street Zen downgraded DBV Technologies from a "hold" rating to a "sell" rating in a report on Friday, July 18th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of DBV Technologies in a report on Saturday, September 27th. JMP Securities reaffirmed a "market outperform" rating and set a $21.00 target price on shares of DBV Technologies in a report on Thursday, June 26th. Lifesci Capital raised DBV Technologies to a "strong-buy" rating in a report on Thursday, June 26th. Finally, Zacks Research raised DBV Technologies from a "strong sell" rating to a "hold" rating in a report on Monday, September 29th.

DBV Technologies Stock Up 5.3%

Shares of NASDAQ DBVT opened at $12.90 on Friday. DBV Technologies has a 12 month low of $2.20 and a 12 month high of $14.44. The company has a market cap of $353.46 million, a price-to-earnings ratio of -2.70 and a beta of -0.45. The business has a fifty day simple moving average of $9.67 and a 200-day simple moving average of $9.09.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last announced its earnings results on Tuesday, July 29th. The company reported ($1.55) EPS for the quarter, missing the consensus estimate of ($0.21) by ($1.34). DBV Technologies had a negative net margin of 3,220.49% and a negative return on equity of 287.15%. The company had revenue of $1.74 million for the quarter, compared to analysts' expectations of $0.64 million. As a group, sell-side analysts expect that DBV Technologies will post -7.05 EPS for the current fiscal year.

Institutional Investors Weigh In On DBV Technologies

Several hedge funds have recently bought and sold shares of DBVT. Vivo Capital LLC purchased a new stake in DBV Technologies in the 2nd quarter worth about $9,659,000. Adage Capital Partners GP L.L.C. purchased a new stake in DBV Technologies in the 2nd quarter worth about $9,659,000. MPM Bioimpact LLC purchased a new stake in DBV Technologies in the 2nd quarter worth about $9,649,000. Octagon Capital Advisors LP purchased a new stake in DBV Technologies in the 2nd quarter worth about $9,315,000. Finally, Nan Fung Trinity HK Ltd. purchased a new stake in DBV Technologies in the 2nd quarter worth about $340,000. 71.74% of the stock is owned by hedge funds and other institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.